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Background. The magnitude of the problem of chronic kidney disease (CKD) is enormous, and the prevalence keeps rising. To
highlight the burden of CKD in developing countries, the authors looked at end-stage renal disease (ESRD) patients seen at the
University of Nigeria Teaching Hospital (UNTH), Enugu, South-East Nigeria. Method. ESRD patients seen from 01/05/1990 to
31/12/2003 were recruited. Records from A&E Department, medical-out-patients, wards and dialysis unit were used. Results.A
total of 1001 male versus 537 female patients were reviewed. About 593 male versus 315 female patients had haemodialysis. The
mean age was 42.55 ± 15.43 years and 86.5% were <60 years. Primary renal disease could not be determined in 51.6% while
hypertension and glomerulonephritis accounted for −17.2% and 14.6%, respectively. Death from renal causes constituted 22.03%
of medical deaths. Conclusion. The prognosis for CKD patients in Nigeria is abysmal. Only few patients had renal-replacement-
therapy (RRT). The prohibitive cost precludes many patients. This underscores the need for preventive measures to reduce the
impact of CKD in the society.
1.Introduction
The magnitude of the problem of chronic kidney disease
(CKD) is enormous, and the prevalence of kidney failure is
rising. Currently, CKD is emerging as a worldwide public
health problem. The World Health Report 2002 and Global
Burden of Disease project reports show that diseases of the
kidney and urinary tract contribute to the global burden
of diseases—with approximately 850,000 deaths every year
and 15,010,167 disability-adjusted life years. Globally, they
represent the 12th cause of death and 17th cause of disability
[1]. This may however be an underrepresentation of the
contribution of CKD to global burden of disease.
Apart from the eﬀect on kidney function per se, kidney
damage is a major determinant for the development of
progressionofacceleratedatherosclerosis,ischaemicvascular
disease, and cardiovascular death [2]. Individuals with
even the earliest signs of CKD are at increased risk of
cardiovascular disease and may die long before they reach
end-stage renal disease. The burden of CKD is therefore not
limitedtoitsimpactondemandofrenalreplacementtherapy
(RRT); it is paralleled by the huge cost of provision of health
care services for these patients. The cost of care includes not
onlythedirectcostofdialysisandtransplantservicesbutalso
indirect cost like man hours lost at the workplace.
In Nigeria, the situation is such that CKD represents
about 8–10% of hospital admission [3, 4]. This may be a
huge underrepresentation of the true situation. It is well
known that CKD is underrecognized and underdiagnosed,
patients with end-stage renal failure (ESRD) are thought to
represent the tip of the iceberg of the entire burden of CKD
[5, 6]. This is more so in developing countries where patients
often present late or not at all to health facilities for several
reasons which range from prohibitive cost of health care
services to use of alternative treatment like spiritual healing
and traditional/native healers [7, 8].
T h ec o s to fm a n a g e m e n to fE S R Di sp r o h i b i t i v e[ 9]. In
developing countries in places where RRT is available it is
unaﬀordable by most patients. In Nigeria as in most other
developing countries, there is no social security system or
health insurance scheme in place to assist the patient, and
the burden is borne solely by the patient and relatives.2 Journal of Tropical Medicine
With this background, this study was carried out to
highlight the plight of patients with ESRD in a typical devel-
oping country and to underscore the need for preventive
measures,earlydetection,andinterventiontostemtherising
prevalence and to alleviate the burden of the disease.
2. Method
All consecutive patients with ESRD seen by the Renal Unit of
the Department of Medicine University of Nigeria Teaching
Hospital (UNTH), Enugu, South-East Nigeria from the
inception of its Dialysis program in May 1990 to December
2003 (period of 13 years) were studied. The UNTH is a
760-bed hospital that serves about a third of the Nigerian
population approximately 128 million (2005 estimate) [10].
Ethical clearance was obtained from the Ethics committee
of the University of Nigeria Teaching Hospital. Patients’
charts were reviewed after prior consent by the two authors
together. Patients seen either in clinic or admitted with
CKD were recruited but only patients with ESRD as deﬁned
by Kidney Disease Improving Global Outcome (KDIGO)
were analyzed. ESRD patients with ambiguous records were
excluded, as well as patients with acute on chronic renal
failureoracuterenalfailure.Patientswhohadsymptomsand
signs of renal disease ≥3 months, with glomerular ﬁltration
rate of <15ml/min, imaging kidney sizes <9cm in length
and who were on any form of renal replacement therapy
were included. The determination of the primary cause of
renaldiseasewasbasedonhistory,physicalexamination,and
laboratoryinvestigationssuchasultrasonography,urinalysis,
blood chemistry, and serology. Histological documentation
of primary renal disease was only possible in very few
cases, some from kidney biopsy and some from postmortem
studies. Chronic glomerulonephritis (CGN) diagnosis was
largely clinical, based on classical symptoms of loin pain,
haematuria, proteinuria, and reduced urine output and in a
few on histological features of inﬂammation in the kidney
on light microscopy. Unfortunately immunoﬂuoresence and
electronmicroscopyarenotavailableinourcentre.Splitskin
smear for acid fast bacilli is done for leprosy. Serology is
a vailableforH epB,HCV ,andHIVinourcentreandW estern
blot conﬁrmatory tests were done for those who screened
HIV positive. HIV-associated nephropathy (HIVAN) was
diagnosed if patient was conﬁrmed HIV positive with
low CD4 T cell count and had proteinuria, oedema, and
normal-sized or enlarged kidneys on ultrasound. Light
microscopy histology of HIVAN from kidney biopsy and
from postmortem data was used in some patients. As a
routine in the unit, all patients who have CKD are screened
for HIV I and II after counseling. Hypertension was noted
as cause of renal disease in some cases with log documented
medical record if hypertension predated kidney disease and
also absence of proteinuria, normal renal function indices,
and preserved renal sizes in presence of hypertension early
in the illness. Diabetic nephropathy (DN) was diagnosed if
patient had a long history of DM and evidence of signiﬁcant
proteinuria as well as presence of other complications of
DM for those with insulin-requiring DM. While for those
with noninsulin-requiring DM, diagnosis was based on
presence of signiﬁcant proteinuria and presence of other
complications of DM, and in very few from postmortem.
Diagnosis of kidney disease from nephrotoxins was made
by exclusion of known and common causes of CKD, a
strong positive history of use of nephrotoxins (such as native
medications, NSAIDs, etc.) and evidence of suggestive urine
picture.
Patients were followed up from presentation at the
Renal Clinic, Accident & Emergency Department or through
referral from other units or departments in the hospital.
Records of all medical and renal cases admitted over the
period were reviewed. Also records of deaths of medical
and renal patients were collected. The total number of
new cases seen in the clinic, the number admitted, and
the patients who had any form of replacement therapy
by way of haemodialysis or kidney transplantation were
documented. The prevalent form of dialysis in the center has
beenhaemodialysisbecauseofproblemsofnonavailabilityof
peritoneal dialysis ﬂuids and repeated infections.
3.StatisticalAnalysis
The Statistical Package for Social Sciences (SSPS Inc,
Chicago, IL) version 16 statistical software was used for data
analysis. For continuous variables, mean values and standard
deviations were calculated and the means were compared
using ANOVA or two-sample t-test. Categorical variables
were compared using the nonparametric tests—Chi-squares
and Kruskal Wallis. The cross-tabulation was used to analyse
therelationship betweenthe stagesofchronic kidney disease.
All tests were two tailed with P< . 05 taken as statistically
signiﬁcant.
4. Results
The ﬂow of patients in the medical and renal outpatient
departments, the medical wards, as well as the number
of deaths from medical and renal causes during the study
period are as shown in Table 1. Renal outpatient attendance
represents 23.17% of all medical outpatient attendance.
A total of 1538 patients with ESRD were admitted over
the study period (1001 male and 537 female patients).
Only 908 patients (593 male and 315 female patients) had
haemodialysis, that is, 59.04% (20.48% female and 38.56%
malepatients)accepteddialysisandcouldpayforitthusthey
were on HD. The remainder though in ESRD and needing
RRT did not get dialysis because either they could not pay
for HD or opted for pre-emptive transplant or did not give
consent for HD.
ESRD cases accounted for 7.96% of all medical admis-
sions and 41.69% of renal admissions. Deaths from renal
disease constituted about 22.03% of all medical deaths on
admission.
4.1. Age Distribution of Patients. The mean age of patients
was 42.55 ± 15.43 years with males being 43.66 ± 15.38
years and the females younger 40.48 ± 15.31 years; theJournal of Tropical Medicine 3





New cases 19,661 (54.5) 16,436 (45.5)
Old cases 85,322 (48.3) 91,254 (51.7)
Renal Outpatient:
New cases 6065 (55.8) 4813 (44.3)
Old cases 32,218 (46.7) 36,766 (53.3)
Medical Admissions 11430 (59.2) 7887 (40.8)
Renal Admissions 2229 (60.4) 1460 (39.6)
ESRD Admissions 1001 (65.1) 537 (34.9)
Patients on dialysis 593 (65.3) 315 (34.7)
Medical Deaths 3258 (63.6) 1862 (36.4)
Renal Deaths 746 (66.1) 382 (33.9)
ESRD: end-stage renal disease.
diﬀerence was signiﬁcant statistically, P<. 001. Most of the
patients seen (86.5%) were less than 60 years of age, Table 2.
4.2. Primary Renal Disease. In most of the patients (51.6%)
the primary renal disease could not be determined; how-
ever in those whose primary renal disease was known
hypertension was most prevalent (17.2%), Table 2. Of the
1538 patients reported in this study, 32 had conﬁrmed
HIV while 29 were documented to have HIVAN. This
number constituted 13% of the patients with CGN. In 22
patients, history of ingestion of a nephrotoxic agent and
urinalysis showing leucocyturia with eosinophilia among
other ﬁndings were suggestive of nephrotoxic damage. Type
II DM was noted in 147 (80.8%) while 35 (19.2%) had type
ID M .
Postmortem (PM) was performed in about 49 patients
over the period 1990 to 2003. Clinical suspicion was
conﬁrmed in about 50% of the PMs done. The histology
of these cases revealed chronic glomerulonephritis-33%,
diabetic nephropathy-22%, hypertension-18%, and chronic
pyelonephritis/chronic interstitial nephritis-11%, and mixed
picture of chronic pyelonephritis and diabetic nephropathy,
chronic pyelonephritis and hypertensive nephrosclerosis or
hypertensive nephrosclerosis, chronic pyelonephritis, and
diabetic nephropathy were documented in 16%.
4.3. Renal Replacement Therapy: Prevalence and Duration
of Dialysis and Prevalence of Transplant. More than three
quarters of the patients defaulted after ﬁve sessions of
haemodialysis. Further analysis showed that a good number
of patients discontinued dialysis after about three months
of haemodialysis, Table 3(a). Reasons for withdrawal were
mostly ﬁnancial, a few were referred out to other centres
because of distance from facility and for kidney trans-
plantation (our centre does not oﬀer transplant service),
Table 3(b).
The mean session of dialysis was very low being 6.01 ±
14.69witharangeof1–398sessions.Fifty-eightpatients,that
is, 6.39% of dialysed patients had permanent access created
for maintenance haemodialysis. Although only 6.39% of
patients had permanent vascular access in the form of A-V
ﬁstula and A-V graft, the rest were dialyzed by temporary
accesses including subclavian vein, internal jugular vein, and
femoral vein cannulation. All patients in ESRD who accept
maintenance HD as modality of deﬁnitive treatment get
prescription for creation of permanent vascular access but
majority are unable to aﬀord the cost and few believe they
may not need it if they would get kidney transplant in the
long run.
Only 6 patients (0.39%) had kidney transplantation.
5. Discussion
This study was undertaken to highlight the high prevalence
of ESRD in developing countries such as Nigeria as well
as to emphasize the abysmal outcome for such patients.
Only a small fraction of patients admitted with ESRD
had renal replacement therapy. Nigeria’s health expenditure
(< $4/capita/year) is ranked among the lowest in the world
[11]. The cost of management of ESRD is prohibitive all over
the world. But unfortunately in Nigeria as in many other
developing countries, the burden of cost of health services is
borne solely by the patients and their relatives. The recently
introduced National Health Insurance Scheme in Nigeria
does not cover CKD patients. Furthermore, about 60% of
N i g e r i a n sl i v eb e l o wt h ep o v e r t yl i n e[ 10]( w o r l df a c t b o o k ) .
Financial constraint has been documented by various studies
as a major impediment in renal replacement therapy in
developing countries. In an analysis of cost implication of
treatmentofESRDinNigeria,Ijomaetal.[9] concluded that
cost of treatment of ESRD was exorbitant and far beyond
the reach of the average Nigerian. As noted by Wairaga [12]
in Kenya, resource is scarce yet the ESRD patient load rises
at alarming rate in Africa. Another article on ESRD in Sub-
SaharanAfricashowedanaverageincreaseof75%from2000
to 2004 with a range of 35.2% to 150% in the countries
represented in the survey [13].
Above data underscore the need for emphasis to be
placed on preventive measures. Prevention can be pri-
mordial, primary, secondary, or tertiary and articulated at
various tiers of government—national, state or province
or region, local government area, division or council.
Nongovernmental organizations can and have been used
for such enlightenment campaigns to raise awareness in the
communities. Community heads and the leadership of the
community can also be utilized to raise awareness especially
for those measures that can be carried out at the individual
and community level such as lifestyle modiﬁcation, per-
sonal, and environmental cleanliness. Other measures would
include getting authorities and professional bodies to mount
public enlightenment campaign to identify nephrotoxic
agents and discourage their use and establishment of good
primary health care policy by the government, with health
centres accessible and aﬀordable for patients. Measures as4 Journal of Tropical Medicine
Table 2: Age group of patients by diseases.
Primary renal disease Age groups number (%)
12–35 36–60 ≥61 Total
Uncertain causes 375 (24.4) 340 (22.1) 79 (5.1) 794 (51.6)
CGN 149 (9.7) 67 (4.35) 10 (0.65) 226 (14.8)
Hypertension 8 (0.5) 210 (13.65) 47 (3.05) 265 (17.2)
Diabetes Mellitus 13 (0.8) 115 (7.5) 54 (3.5) 182 (11.8)
Others 18 (1.15) 35 (2.3) 18 (1.15) 71 (4.6)
Total 563 (36.6) 767 (49.9) 208 (13.5) 1538 (100)
∗Others sickle cell nephropathy—2 (2.8%), ADPKD—5 (7.0%), toxic nephropathy—22 (31.0%), obstructive uropathy—20 (28.2%), chronic
pyelonephritis—22 (31.0%).
Table 3




1–5 6–10 11–49 ≥50 Total (%)
<1 694 18 3 0 715 (78.7)
1–3 12 68 36 0 116 (12.8)
3–6 0 1 36 0 37 (4.1)
6–9 1 0 19 1 21 (2.3)
9–12 0050 5 ( 0 . 5 )
12–24 0045 9 ( 1 . 0 )
>24 0014 5 ( 0 . 5 )
Total 707 (77.9) 87 (9.6) 104 (11.4) 10 (1.1) 908 (100)
(b) Reasons for withdrawal.
Reasons %
Financial 91.5
Distance from dialysis facility 0.8
Death 3.7
Referred out∗ 1.2
Withdrawal of consent 0.1
Others 2.7
∗Others referred out for kidney transplantation.
regular evaluation in a health facilities and regular screening
forcommunicableandnoncommunicablediseasesshouldbe
advocated. Early treatment of identiﬁed diseases and timely
referral to nephrologists in established CKD.
Most patients in Nigeria present late to health facilities.
Often times before presenting to a health facility they would
havetriedvariousformsofalternativetreatmentlikespiritual
healing and traditional/native healers mainly because of
reasons related to accessibility and aﬀordability of health
care services [7, 8]. Indeed, a large proportion of patients
with chronic illnesses die without presenting to any health
facility.Inthispresentstudy,onlyalittleover50%ofpatients
seen with ESRD who should have dialysis had it and only
a very small fraction had near optimal dialysis. Majority
of patients defaulted after few sessions of haemodialysis.
Arije et al. [15] made similar observations in their study
in South-West Nigeria. They noted that 70.8% of their
Table 4: Comparison of present study with data from a developed
country.
Present study ANZData Registry
[14]
Mean age (yrs) 42.55 65
Peak age group 36–60 years 65–74 years
Age prevalence 86% ≤ 60 years 45% ≥ 65 years
Time of presentation CKD stage 4 & 5 25% < 3m o n t h s
prior to 1st dialysis
% with Permanent
access 6.39 30–50




ANZData registry: Australia, New Zealand Data registry; CKD: chronic
kidney disease.
patients defaulted after less than a month on dialysis. In the
light of the ﬁndings in this present study and others [15]
we propose the following, for maintenance HD indications
in ESRD in Nigeria: (1) conﬁrmed ESRD as per KDIGO
deﬁnition, (2) ability to sustain dialysis for a minimum of
three months, (3) reliable and accessible HD centre at an
acceptable distance, (4) informed consent to continue with
dialysis after appropriate explanation, (5) absence of other
serious comorbidities that will lead to patient’s demise even
before ESRD, and (6) absence of terminal diseases.
Age distribution of patients seen revealed that most of
them were in their productive years—less than 60 years of
age unlike what is observed in developed world [14, 16,
17]. Table 4 shows that the peak age of presentation in
developed countries is 65–74 years unlike 36–60 years noted
in this present study. The implication of this to the country’s
economy is obvious. Similar age distribution has been
documented in other studies on ESRD in Nigeria [3, 7]a n d
in other developing countries [18]. Reasons adduced for the
younger age of patients with ESRD in the developing world
include high prevalence of infections/infestations especially
in childhood leading to CGN which is the commonest cause
of ESRD in this part of the world [19, 20]. In addition
























Figure 1: Comparison of causes of chronic kidney disease in
diﬀerent regions (present study in Nigeria, United States [17],
Europe [25], and Australia [14]).
the disease is advanced. Inadequate investigation and treat-
ment/control of such causes of ESRD as hypertension and
diabetes also contribute. Hypertensive nephrosclerosis is the
2 n dc o m m o n e s tc a u s eo fE S R Di no u re n vi r o n m e n t[ 19, 20].
Hypertensionruns amore aggressivecauseinblacks andalso
hypertensivenephrosclerosisismorecommoninblacks[21].
Diabetic nephropathy is also commoner in blacks and runs a
more aggressive course and often occurs at a young age than
in Caucasians [22] .T h eb r u n to fH I Vp a n d e m i ci sb o r n e
by Sub-saharan Africa and many of such patients develop
ESRD from HIVAN and other glomerulopathies [23]. Use of
nephrotoxic agents including traditional/native medication,
mercury-containing soaps/skin lightening creams, is ram-
pant in the study community [24]. Awareness of deleterious
eﬀect of these agents is low in these areas. However, because
of late presentation of our patients, the full impact of ESRD
fromuseofnephrotoxicagentsisnotquiteobvious,asearlier
and mild forms of the disease do not present to hospitals.
Chronic haemodialysis became available in Nigeria in late
1981, and by 2003 there were 27 dialysis units in the country.
By 2006, with a population of the nation estimated at about
130 million there were 84 nephrologists and 56 dialysis units
[13]. These units are mainly located in urban areas and are
runwithrefurbishedpoorlymaintained machines.InSouth-
East Nigeria (the study area), there were only two centres
that oﬀered dialysis in 2003 but currently there are 7 dialysis
centres: 2 government owned and 5 privately owned centres.
Of the seven, only one is in a rural area.
In 1998 kidney transplant service was started in a private
clinic in Lagos but was soon followed by three centres in
Government owned Teaching Hospitals. Presently only the
privately owned centre is fully functional.
ESRD disease cases in this present study accounted for
about 8% of patients admitted into the medical wards. This
falls within the range of 2–12% that has been reported in the
past in Nigeria [3, 4]. It is important to note, however, that
renal cases accounted for 23% of all new medical cases that
presented to the outpatient department. In majority of the
patients the primary cause of kidney disease was not known
(Table 2). But for those whom the primary kidney disease
was known, hypertension was most prevalent followed by
chronic glomerulonephritis and diabetes mellitus. It is prob-
able that both chronic glomerulonephritis and hypertension
could account for a good number of the cases in which the
primary kidney disease was not known. Several studies in
Nigeria have documented chronic glomerulonephritis and
hypertension as the commonest causes of ESRD [3, 7].
Similarly, in other developing countries glomerulonephritis
isstilltheprevalentcauseofESRD[18].Thisisunlikewhatis
obtained in the developed countries where diabetes mellitus
seems to be most prevalent [7, 17, 25]( Figure 1), reﬂecting
the high prevalence of infectious diseases in developing
countries.
Most of our patients could not cope with the ﬁnancial
burden of renal replacement therapy resulting in high rate
of treatment withdrawal. In India, treatment withdrawal was
reported as the cause of death in 70% of patients [18]. It
is rather an unfortunate situation but it is the REALITY of
what is obtained in developing countries and in most Sub-
Saharan African countries. Only a small fraction of patients
with ESRD in this study had renal transplant (0.39%).
In conclusion this study highlights the poor outcome
and grim outlook for patients with ESRD in Nigeria and
indeed most Sub-Saharan African countries. It also brings
to the fore the young age of patients with ESRD, the
late presentation, and high rate of treatment withdrawal
of patients. It therefore underscores the pressing need for
aggressive and comprehensive strategies for early detection
and treatment of causes of CKD at the primordial and
primary prevention levels, as advocated by International
Society of Nephrology, to reduce the impact of CKD in the
society. The institution of such preventive measures for early
diagnosis and adequate treatment of ESRD causes as prompt
and early treatment of infections and infestations, tight
glycaemic control (HbA1c <7%) for patients with diabetes
mellitus and adequate blood pressure control to <130/80
should be reinforced. Other measures such as education
of the policy makers, other medical practitioners, and the
general public would help raise awareness. Furthermore,
because most patients who start maintenance haemodialysis
as form of RRT in Nigeria are unable to sustain it, strict
patient selection is advised and the criteria for initiating
maintenance haemodialysis in resource poor countries have
been proposed in this article.
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